目的:研究前列腺癌病灶内G蛋白偶联受体C6A(G protein-coupled receptor class C group 6member A,GPRC6A)和蛋白激酶Cζ(Protein Kinase Czeta,PKCzeta)表达水平与细胞增殖、上皮间质转化(EMT)的关系。方法:选择2014年6月~2017年3月期...目的:研究前列腺癌病灶内G蛋白偶联受体C6A(G protein-coupled receptor class C group 6member A,GPRC6A)和蛋白激酶Cζ(Protein Kinase Czeta,PKCzeta)表达水平与细胞增殖、上皮间质转化(EMT)的关系。方法:选择2014年6月~2017年3月期间在我院接受手术切除治疗的前列腺癌患者以及良性前列腺增生患者,留取前列腺癌患者的前列腺癌病灶、癌旁病灶适量,检测病灶中GPRC6A、PKCzeta、细胞增殖基因、EMT基因的表达量。结果:前列腺癌病灶、癌旁病灶中GPRC6A、Survivin、SRSF1、Bcl-xl、N-cadherin、Vimentin的表达量显著高于良性前列腺增生病灶,PKCzeta、Caspase-3、Caspase-9、Apaf-1、E-cadherin、CK5/6的表达量显著低于良性前列腺增生病灶;PKCzeta低表达的前列腺癌病灶中Survivin、SRSF1、Bcl-xl的表达量显著高于PKCzeta高表达的前列腺癌病灶,Caspase-3、Caspase-9、Apaf-1的表达量显著低于PKCzeta高表达的前列腺癌病灶;GPRC6A低表达的前列腺癌病灶中E-cadherin、CK5/6的表达量显著高于GPRC6A高表达的前列腺癌病灶,N-cadherin、Vimentin的表达量显著低于GPRC6A高表达的前列腺癌病灶。结论:前列腺癌病灶内高表达的GPRC6A和低表达的PKCzeta分别能够促进细胞EMT和增殖。展开更多
Objective: To study the relationship of GPRC6A and PKCzeta expression levels in prostate cancer lesions with cell proliferation and epithelial-mesenchymal transition (EMT). Methods:Patients with prostate cancer and pa...Objective: To study the relationship of GPRC6A and PKCzeta expression levels in prostate cancer lesions with cell proliferation and epithelial-mesenchymal transition (EMT). Methods:Patients with prostate cancer and patients with benign prostatic hyperplasia who received surgical resection in Huizhou Third People's Hospital between June 2014 and March 2017 were selected, right amount of prostate cancer tissue and tissue adjacent to carcinoma was collected from patients with prostate cancer, and the expression of GPRC6A, PKCzeta, cell proliferation genes and EMT genes in lesions were detected. Results: GPRC6A, Survivin, SRSF1, Bcl-xl, N-cadherin and Vimentin expression in prostate cancer lesions and adjacent lesions were significantly higher than those in benign prostatic hyperplasia lesions while PKCzeta, Caspase-3, Caspase-9, Apaf-1, E-cadherin and CK5/6 expression were significantly lower than those in benign prostatic hyperplasia lesions;Survivin, SRSF1 and Bcl-xl expression in prostate cancer lesions with lower PKCzeta expression were significantly higher than those in prostate cancer lesions with higher PKCzeta expression while Caspase-3, Caspase-9 and Apaf-1 expression were significantly lower than those in prostate cancer lesions with higher PKCzeta expression;E-cadherin and CK5/6 expression in prostate cancer lesions with lower GPRC6A expression were significantly higher than those in prostate cancer lesions with higher GPRC6A expression while N-cadherin and Vimentin expression were significantly lower than those in prostate cancer lesions with higher GPRC6A expression. Conclusion:Highly expressed GPRC6A and lowly expressed PKCzeta in prostate cancer lesions can promote cell EMT and proliferation respectively.展开更多
目的研究孕早期妇女血清补体C1q/肿瘤坏死因子相关蛋白6(C1q/tumor necrosis factor-related protein 6,CTRP6)的表达水平,探讨其与妊娠糖尿病(gestational diabetes mellitus,GDM)的关系。方法前瞻性连续选取2021年3月至2022年3月在郑...目的研究孕早期妇女血清补体C1q/肿瘤坏死因子相关蛋白6(C1q/tumor necrosis factor-related protein 6,CTRP6)的表达水平,探讨其与妊娠糖尿病(gestational diabetes mellitus,GDM)的关系。方法前瞻性连续选取2021年3月至2022年3月在郑州大学第二附属医院门诊产检的孕10~13周孕妇,收集孕妇的年龄、身高、体质量、末次月经时间,检测孕早期总胆固醇(total cholesterol,TC)、三酰甘油(triglyceride,TG)、高密度脂蛋白(high density lipoprotein,HDL)、低密度脂蛋白(low density lipoprotein,LDL)、空腹血糖(fasting plasma glucose,FPG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、空腹胰岛素(fasting insulin,FINS)、CTRP6水平,计算孕前体质量指数(body mass index,BMI)、基线BMI、产前BMI和胰岛素抵抗指数(亦称胰岛素抵抗的稳态模型评估,homeostatic model assessment of insulin resistance,HOMA-IR)。所有孕妇均于孕24~28周行75g口服葡萄糖耐量试验,根据试验结果分为GDM组和糖耐量正常(normal glucose tolerance,NGT)组。比较两组孕妇孕早期的临床资料及实验室指标,分析孕早期血清CTRP6与各指标的相关性及其与GDM的关系。结果共纳入孕妇213例,完整随访203例,其中52例孕妇被诊断为GDM,GDM发病率25.62%。GDM组孕妇的孕早期血清CTRP6、年龄、孕前BMI、基线BMI、产前BMI、TC、LDL、FPG、HbA1c、FINS、HOMA-IR均较NGT组升高,差异有统计学意义(P<0.05)。孕早期CTRP6与年龄、孕前BMI、基线BMI、产前BMI、TG、LDL、FPG、HbA1c、FINS、HOMA-IR呈正相关,与HDL呈负相关(P<0.05)。校正年龄、BMI、糖脂代谢指标及HOMA-IR后,孕早期CTRP6为GDM发病的独立影响因素。结论孕早期血清CTRP6升高与GDM相关,是GDM的独立危险因素。展开更多
目的:检测急性心肌梗死(acute myocardial infarction,AMI)患者血清C1q/肿瘤坏死因子相关蛋白-6(C1q/tumor necrosis factor related protein 6,CTRP6)表达水平与病情和预后的相关性。方法:选取河南科技大学第一附属医院2021年1月至2022...目的:检测急性心肌梗死(acute myocardial infarction,AMI)患者血清C1q/肿瘤坏死因子相关蛋白-6(C1q/tumor necrosis factor related protein 6,CTRP6)表达水平与病情和预后的相关性。方法:选取河南科技大学第一附属医院2021年1月至2022年1月收治的144例AMI患者为研究对象,检测血清CTRP6的表达含量,并分析及评估CTRP6表达与AMI患者的临床特征和MACE的相关性。结果:AMI组患者外周血CTRP6含量为119.32(78.4,165.8)μg/L,显著低于对照组的372.3(303.6,454.2)μg/L(P<0.05);与高表达组比较,低表达组患者血清CK-MB、NT-proBNP、Gensini评分和SYNTAX II评分明显升高(P<0.05),而LVEF明显降低(P<0.05);此外,CTRP6低表达组患者MACE的累积发生率显著高于CTRP6高表达组(P<0.05);CTRP6预测AMI患者发生MACE事件的ROC曲线下面积为0.851。当最佳截断值为当88.423μg/L时,此时的敏感性为75.3%,特异性87.4%。结论:AMI患者血清CTRP6的表达明显降低,且CTRP6低表达可能是识别AMI高危患者和优化治疗策略的重要靶点。展开更多
文摘目的:研究前列腺癌病灶内G蛋白偶联受体C6A(G protein-coupled receptor class C group 6member A,GPRC6A)和蛋白激酶Cζ(Protein Kinase Czeta,PKCzeta)表达水平与细胞增殖、上皮间质转化(EMT)的关系。方法:选择2014年6月~2017年3月期间在我院接受手术切除治疗的前列腺癌患者以及良性前列腺增生患者,留取前列腺癌患者的前列腺癌病灶、癌旁病灶适量,检测病灶中GPRC6A、PKCzeta、细胞增殖基因、EMT基因的表达量。结果:前列腺癌病灶、癌旁病灶中GPRC6A、Survivin、SRSF1、Bcl-xl、N-cadherin、Vimentin的表达量显著高于良性前列腺增生病灶,PKCzeta、Caspase-3、Caspase-9、Apaf-1、E-cadherin、CK5/6的表达量显著低于良性前列腺增生病灶;PKCzeta低表达的前列腺癌病灶中Survivin、SRSF1、Bcl-xl的表达量显著高于PKCzeta高表达的前列腺癌病灶,Caspase-3、Caspase-9、Apaf-1的表达量显著低于PKCzeta高表达的前列腺癌病灶;GPRC6A低表达的前列腺癌病灶中E-cadherin、CK5/6的表达量显著高于GPRC6A高表达的前列腺癌病灶,N-cadherin、Vimentin的表达量显著低于GPRC6A高表达的前列腺癌病灶。结论:前列腺癌病灶内高表达的GPRC6A和低表达的PKCzeta分别能够促进细胞EMT和增殖。
文摘Objective: To study the relationship of GPRC6A and PKCzeta expression levels in prostate cancer lesions with cell proliferation and epithelial-mesenchymal transition (EMT). Methods:Patients with prostate cancer and patients with benign prostatic hyperplasia who received surgical resection in Huizhou Third People's Hospital between June 2014 and March 2017 were selected, right amount of prostate cancer tissue and tissue adjacent to carcinoma was collected from patients with prostate cancer, and the expression of GPRC6A, PKCzeta, cell proliferation genes and EMT genes in lesions were detected. Results: GPRC6A, Survivin, SRSF1, Bcl-xl, N-cadherin and Vimentin expression in prostate cancer lesions and adjacent lesions were significantly higher than those in benign prostatic hyperplasia lesions while PKCzeta, Caspase-3, Caspase-9, Apaf-1, E-cadherin and CK5/6 expression were significantly lower than those in benign prostatic hyperplasia lesions;Survivin, SRSF1 and Bcl-xl expression in prostate cancer lesions with lower PKCzeta expression were significantly higher than those in prostate cancer lesions with higher PKCzeta expression while Caspase-3, Caspase-9 and Apaf-1 expression were significantly lower than those in prostate cancer lesions with higher PKCzeta expression;E-cadherin and CK5/6 expression in prostate cancer lesions with lower GPRC6A expression were significantly higher than those in prostate cancer lesions with higher GPRC6A expression while N-cadherin and Vimentin expression were significantly lower than those in prostate cancer lesions with higher GPRC6A expression. Conclusion:Highly expressed GPRC6A and lowly expressed PKCzeta in prostate cancer lesions can promote cell EMT and proliferation respectively.
文摘目的研究孕早期妇女血清补体C1q/肿瘤坏死因子相关蛋白6(C1q/tumor necrosis factor-related protein 6,CTRP6)的表达水平,探讨其与妊娠糖尿病(gestational diabetes mellitus,GDM)的关系。方法前瞻性连续选取2021年3月至2022年3月在郑州大学第二附属医院门诊产检的孕10~13周孕妇,收集孕妇的年龄、身高、体质量、末次月经时间,检测孕早期总胆固醇(total cholesterol,TC)、三酰甘油(triglyceride,TG)、高密度脂蛋白(high density lipoprotein,HDL)、低密度脂蛋白(low density lipoprotein,LDL)、空腹血糖(fasting plasma glucose,FPG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、空腹胰岛素(fasting insulin,FINS)、CTRP6水平,计算孕前体质量指数(body mass index,BMI)、基线BMI、产前BMI和胰岛素抵抗指数(亦称胰岛素抵抗的稳态模型评估,homeostatic model assessment of insulin resistance,HOMA-IR)。所有孕妇均于孕24~28周行75g口服葡萄糖耐量试验,根据试验结果分为GDM组和糖耐量正常(normal glucose tolerance,NGT)组。比较两组孕妇孕早期的临床资料及实验室指标,分析孕早期血清CTRP6与各指标的相关性及其与GDM的关系。结果共纳入孕妇213例,完整随访203例,其中52例孕妇被诊断为GDM,GDM发病率25.62%。GDM组孕妇的孕早期血清CTRP6、年龄、孕前BMI、基线BMI、产前BMI、TC、LDL、FPG、HbA1c、FINS、HOMA-IR均较NGT组升高,差异有统计学意义(P<0.05)。孕早期CTRP6与年龄、孕前BMI、基线BMI、产前BMI、TG、LDL、FPG、HbA1c、FINS、HOMA-IR呈正相关,与HDL呈负相关(P<0.05)。校正年龄、BMI、糖脂代谢指标及HOMA-IR后,孕早期CTRP6为GDM发病的独立影响因素。结论孕早期血清CTRP6升高与GDM相关,是GDM的独立危险因素。
文摘目的:检测急性心肌梗死(acute myocardial infarction,AMI)患者血清C1q/肿瘤坏死因子相关蛋白-6(C1q/tumor necrosis factor related protein 6,CTRP6)表达水平与病情和预后的相关性。方法:选取河南科技大学第一附属医院2021年1月至2022年1月收治的144例AMI患者为研究对象,检测血清CTRP6的表达含量,并分析及评估CTRP6表达与AMI患者的临床特征和MACE的相关性。结果:AMI组患者外周血CTRP6含量为119.32(78.4,165.8)μg/L,显著低于对照组的372.3(303.6,454.2)μg/L(P<0.05);与高表达组比较,低表达组患者血清CK-MB、NT-proBNP、Gensini评分和SYNTAX II评分明显升高(P<0.05),而LVEF明显降低(P<0.05);此外,CTRP6低表达组患者MACE的累积发生率显著高于CTRP6高表达组(P<0.05);CTRP6预测AMI患者发生MACE事件的ROC曲线下面积为0.851。当最佳截断值为当88.423μg/L时,此时的敏感性为75.3%,特异性87.4%。结论:AMI患者血清CTRP6的表达明显降低,且CTRP6低表达可能是识别AMI高危患者和优化治疗策略的重要靶点。
